Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR and keeping the price target at $170.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sam Slutsky has given his Buy rating due to a combination of factors tied to obefazimod’s differentiated clinical profile in ulcerative colitis and the upcoming Phase 3 maintenance readout. He highlights that the 50 mg once-daily dose delivered a placebo‑adjusted clinical remission rate at the higher end of Phase 3 induction benchmarks, with competitive efficacy across prior treatment histories, a favorable tolerability profile, and a novel oral mechanism that should ease uptake by limiting pre‑treatment and monitoring burdens.
Slutsky also points to a large and expanding ulcerative colitis market where existing therapies appear to have reached a therapeutic ceiling and patients often cycle through several drug classes, underscoring demand for new durable options. He believes obefazimod’s novel mode of action only needs to match the maintenance performance of current standards to be clinically and commercially attractive, especially given encouraging Phase 2 maintenance results and rising KOL support, which together underpin a high perceived probability of success and justify a positive investment stance on Abivax’s shares.
According to TipRanks, Slutsky is a top 100 analyst with an average return of 40.2% and a 51.74% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Olema Pharmaceuticals, and Abivax SA Sponsored ADR.
In another report released on March 24, Guggenheim also maintained a Buy rating on the stock with a $175.00 price target.